^
Association details:
| Biomarker: | NF1 deletion |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | mirdametinib (PD-0325901) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency
Excerpt:
PD0325901 exposure suppressed the growth of LN229 tumors (Fig. 4B) and increased the survival of LN229-bearing animals...
DOI:
10.1158/0008-5472.CAN-12-0334
